Patricia McMonagle

651 total citations
17 papers, 294 citations indexed

About

Patricia McMonagle is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Patricia McMonagle has authored 17 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hepatology, 12 papers in Infectious Diseases and 10 papers in Epidemiology. Recurrent topics in Patricia McMonagle's work include Hepatitis C virus research (13 papers), HIV/AIDS drug development and treatment (11 papers) and Hepatitis B Virus Studies (10 papers). Patricia McMonagle is often cited by papers focused on Hepatitis C virus research (13 papers), HIV/AIDS drug development and treatment (11 papers) and Hepatitis B Virus Studies (10 papers). Patricia McMonagle collaborates with scholars based in United States, Slovakia and Argentina. Patricia McMonagle's co-authors include Stephanie Curry, Robert A. Chase, Paul Ingravallo, Stuart Black, Anita Y. M. Howe, Rong Liu, Frederick Lahser, Ernest Asante‐Appiah, A Howe and Mark J. DiNubile and has published in prestigious journals such as Journal of Biological Chemistry, Analytical Biochemistry and Journal of Medicinal Chemistry.

In The Last Decade

Patricia McMonagle

17 papers receiving 287 citations

Peers

Countries citing papers authored by Patricia McMonagle

Since Specialization

Citations

This map shows the geographic impact of Patricia McMonagle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia McMonagle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia McMonagle more than expected).

Fields of papers citing papers by Patricia McMonagle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia McMonagle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia McMonagle. The network helps show where Patricia McMonagle may publish in the future.

Co-authorship network of co-authors of Patricia McMonagle

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia McMonagle. A scholar is included among the top collaborators of Patricia McMonagle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia McMonagle. Patricia McMonagle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study 2022 ·Antiviral Research ·Yuao Zhu, (unknown), (unknown), K. Devendra, (unknown), Chester Costales, Keith Kobylarz, Patricia McMonagle, Claire M. Steppan, Lisa Aschenbrenner, Annaliesa S. Anderson, Rhonda D. Cardin	18
2	Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2 2019 ·Antimicrobial Agents and Chemotherapy ·Ernest Asante‐Appiah, Paul Ingravallo, Patricia McMonagle, (unknown), Ellen Xia, Stephanie Curry, Ping Qiu, Stuart Black, Robert A. Chase, Rong Liu, Frederick Lahser	2
3	In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A 2018 ·Antimicrobial Agents and Chemotherapy ·Ernest Asante‐Appiah, Rong Liu, Stephanie Curry, Patricia McMonagle, Sony Agrawal, Donna Carr, Laura L. Rokosz, Frederick Lahser, (unknown), Robert A. Chase, Stuart Black, Eric Ferrari, Paul Ingravallo, Ling Tong, Wensheng Yu, Joseph A. Kozlowski	4
4	Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a 2017 ·Journal of Biological Chemistry ·Zhuyan Guo, Stuart Black, Yuan Hu, Patricia McMonagle, Paul Ingravallo, Robert A. Chase, Stephanie Curry, Ernest Asante‐Appiah	8
5	Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons 2017 ·Antimicrobial Agents and Chemotherapy ·Ernest Asante‐Appiah, Stephanie Curry, Patricia McMonagle, Paul Ingravallo, Robert A. Chase, David C. Nickle, Ping Qiu, Anita Y. M. Howe, Frederick Lahser	19
6	Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants 2016 ·Journal of Medicinal Chemistry ·Wensheng Yu, Ling Tong, Bin Hu, Bin Zhong, (unknown), Tao Ji, (unknown), Craig A. Coburn, Oleg Selyutin, Lei Chen, Laura L. Rokosz, Sony Agrawal, Rong Liu, Stephanie Curry, Patricia McMonagle, Paul Ingravallo, Ernest Asante‐Appiah, Shiying Chen, Joseph A. Kozlowski	18
7	In a 5-Day Monotherapy Trial, MK-8408 Demonstrates Potent Antiviral Activity and Improved Resistance Profile in HCV Patients with Genotypes 1, 2, and 3 Infections 2016 ·Journal of Hepatology ·Ernest Asante‐Appiah, William Marshall, Edward Gane, Simona Georgiana Popa, Patricia McMonagle, Stephanie Curry, (unknown), Wenfeng Gao, (unknown), Caroline Cilissen, Inge De Lepeleire, Todd A. Black, Daria J. Hazuda, Joan R. Butterton	3
8	The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons 2016 ·Antimicrobial Agents and Chemotherapy ·Frederick Lahser, (unknown), Stephanie Curry, Patricia McMonagle, Ellen Xia, Paul Ingravallo, Robert A. Chase, Rong Liu, Todd A. Black, Daria J. Hazuda, Anita Y. M. Howe, Ernest Asante‐Appiah	38
9	P0891 : Resistance analysis of virologic failures in Hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: The C-worthy study 2015 ·Journal of Hepatology ·Stuart Black, (unknown), Paul Ingravallo, Patricia McMonagle, Robert A. Chase, Melissa Shaughnessy, Peggy Hwang, Barbara Haber, P. Richard Harrigan, Chanson J. Brumme, A Howe	30
10	Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir 2015 ·Antimicrobial Agents and Chemotherapy ·Rong Liu, Stephanie Curry, Patricia McMonagle, Wendy W. Yeh, Steven W. Ludmerer, Patricia Jumes, William L. Marshall, Stephanie E. Kong, Paul Ingravallo, Stuart Black, (unknown), Mark J. DiNubile, A Howe	59
11	Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin 2014 ·Open Forum Infectious Diseases ·John A. Howe, Jianmin Long, Stuart Black, Robert A. Chase, Patricia McMonagle, Stephanie Curry, Seth Thompson, Mark J. DiNubile, Anita Y. M. Howe	16
12	Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3 2013 ·Journal of Hepatology ·Marcelo Silva, Michelle Treitel, Donald J. Graham, Stephanie Curry, (unknown), Patricia McMonagle, Samir K. Gupta, Eric Hughes, Robert A. Chase, Frederick Lahser, Richard J. O. Barnard, Anita Y. M. Howe, John A. Howe	35
13	Identification of PTC725, an Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein 2013 ·Antimicrobial Agents and Chemotherapy ·Zhengxian Gu, Jason D. Graci, Frederick Lahser, Jamie J. Breslin, (unknown), James H. Crona, Patricia McMonagle, Ellen Xia, (unknown), Gary M. Karp, Jin Zhu, Song Huang, Amin A. Nomeir, Marla Weetall, Neil G. Almstead, Stuart W. Peltz, Xiao Tong, Robert Ralston, Joseph M. Colacino	15
14	1198 HCV NS3/4A PROTEASE RESISTANCE-ASSOCIATED VARIANTS (RAVS) IDENTIFIED IN GENOTYPE 1A PATIENTS EXHIBIT DIFFERENCES IN PHENOTYPIC RESISTANCE TO BOCEPREVIR AND TELAPREVIR IN GENOTYPE 1A REPLICON CELLS 2012 ·Journal of Hepatology ·Stuart Black, Patricia McMonagle, Robert A. Chase, Stephanie Curry, Richard J. O. Barnard, Daria J. Hazuda, A Howe, John A. Howe, Robert A. Ogert	1
15	844 IN VITRO CHARACTERIZATION OF THE PAN-GENOTYPE ACTIVITY OF THE HCV NS3/4A PROTEASE INHIBITORS BOCEPREVIR AND TELAPREVIR 2012 ·Journal of Hepatology ·John A. Howe, Donald J. Graham, Patricia McMonagle, Stephanie Curry, Robert A. Chase, Frederick Lahser, Robert A. Ogert, Julie Strizki, (unknown), (unknown), (unknown), Michelle Treitel, Daria J. Hazuda, A Howe	2
16	A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors 2009 ·Antiviral Research ·Robert A. Chase, Angela Skelton, Ellen Xia, Stephanie Curry, (unknown), Patricia McMonagle, Hsiao‐Ching Huang, Xiao Tong	14
17	A high-throughput assay for the adenylation reaction of bacterial DNA ligase 2007 ·Analytical Biochemistry ·Lynn Miesel, (unknown), (unknown), Patricia McMonagle, (unknown), John Pichardo, Boris Feld, (unknown), Robert E. Palermo	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact